CDC25A and CHEK1

Data Source:
HPRD (in vivo, in vitro)

		CDC25A	CHEK1
Description		cell division cycle 25A	checkpoint kinase 1
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Cytosol	Chromosome, Telomeric Region Chromatin Condensed Nuclear Chromosome Extracellular Space Nucleus Nucleoplasm Cytoplasm Centrosome Cytosol Protein-containing Complex Intracellular Membrane-bounded Organelle
	Molecular Function	Phosphoprotein Phosphatase Activity Protein Tyrosine Phosphatase Activity Protein Binding Protein Kinase Binding Chaperone Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Kinase Activity Protein Domain Specific Binding Histone Kinase Activity (H3-T11 Specific) Protein Serine Kinase Activity Protein Threonine Kinase Activity
	Biological Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G1/S Transition Of Mitotic Cell Cycle G2/M Transition Of Mitotic Cell Cycle Cell Population Proliferation Response To Radiation Positive Regulation Of G2/M Transition Of Mitotic Cell Cycle Protein Deubiquitination Cellular Response To UV Peptidyl-tyrosine Dephosphorylation Cell Division Regulation Of Cell Cycle Positive Regulation Of G2/MI Transition Of Meiotic Cell Cycle	DNA Damage Checkpoint DNA Replication DNA Repair Protein Phosphorylation Apoptotic Process Cellular Response To DNA Damage Stimulus DNA Damage Induced Protein Phosphorylation Regulation Of Double-strand Break Repair Via Homologous Recombination Regulation Of Transcription From RNA Polymerase II Promoter In Response To UV-induced DNA Damage Peptidyl-threonine Phosphorylation Histone H3-T11 Phosphorylation Intracellular Signal Transduction Mitotic G2/M Transition Checkpoint Positive Regulation Of Cell Cycle Negative Regulation Of Mitotic Nuclear Division Regulation Of Mitotic Centrosome Separation Chromatin-mediated Maintenance Of Transcription Negative Regulation Of G0 To G1 Transition Cellular Response To Mechanical Stimulus Signal Transduction Involved In G2 DNA Damage Checkpoint Replicative Senescence Regulation Of Signal Transduction By P53 Class Mediator Regulation Of Histone H3-K9 Acetylation
Pathways		Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Signaling by SCF-KIT Activation of ATR in response to replication stress Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Ubiquitin Mediated Degradation of Phosphorylated Cdc25A Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Transcriptional Regulation by E2F6
Drugs			XL844 Enzastaurin CHIR-124 N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL 2-(cyclohexylamino)benzoic acid 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol 6-MORPHOLIN-4-YL-9H-PURINE 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE Fostamatinib
Diseases
GWAS		Blood protein levels ( 28240269) Body size at age 10 ( 32376654) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Coronary artery disease ( 29212778) Cortical surface area (MOSTest) ( 32665545) Diastolic blood pressure ( 27841878) HDL cholesterol levels ( 32203549) Household income (MTAG) ( 31844048) Loneliness (multivariate analysis) ( 27629369) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (beta blocking agents) ( 31015401) Medication use (diuretics) ( 31015401) Pulse pressure ( 27841878) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Systolic blood pressure ( 27841878 27618447)	Breast cancer (survival) ( 25890600) Squamous cell lung carcinoma ( 28604730)
Interacting Genes		56 interacting genes: APP AR BTRC CAMK1D CCNA1 CCNB1 CCNE1 CCNI CDK1 CDK2 CDK5 CDKN3 CHEK1 CHEK2 CSNK1A1 CUL3 CUX1 DMD DUSP8 EEF1A1 EGFR FAM193B FBXW11 FGF21 FTH1 FZR1 HDAC11 HLA-C HRAS IL3RA LMO2 MAP3K5 MAPK14 MCM3AP MTAP NAA10 NAA11 NFKBIB NFYA PEX19 PIM1 PKM POLR1D RAF1 ROCK1 SCYL1 SMAD3 SOX5 SRC UBB VAMP8 XPO1 YWHAB YWHAE YWHAQ YWHAZ	51 interacting genes: AATF AKT1 APP ATM ATR ATXN3 BCL2L1 BLM BRCA1 BRCA2 CDC25A CDC25B CDC25C CHUK CLSPN CNTN2 CSNK2B CUL1 CUL4A DTL FANCE HSP90AA1 ILKAP LATS2 MAPT MCM6 MCM7 MCPH1 MDM4 PIGM PRKAA1 PRKDC RAD23A RAD51 RB1 RELA SMAD4 TIMELESS TLK1 TOPBP1 TP53 TP53BP1 UBA1 UBA2 UBB UBE2T USP3 XIAP XPO1 XRCC6 YWHAG
Entrez ID		993	1111
HPRD ID		00305	04356
Ensembl ID		ENSG00000164045	ENSG00000149554
Uniprot IDs		A0A024R2R6 D8KXX0 K7N7S0 P30304	B4DT73 E7EPP6 O14757
PDB IDs		1C25	1IA8 1NVQ 1NVR 1NVS 1ZLT 1ZYS 2AYP 2BR1 2BRB 2BRG 2BRH 2BRM 2BRN 2BRO 2C3J 2C3K 2C3L 2CGU 2CGV 2CGW 2CGX 2E9N 2E9O 2E9P 2E9U 2E9V 2GDO 2GHG 2HOG 2HXL 2HXQ 2HY0 2QHM 2QHN 2R0U 2WMQ 2WMR 2WMS 2WMT 2WMU 2WMV 2WMW 2WMX 2X8D 2X8E 2X8I 2XEY 2XEZ 2XF0 2YDI 2YDJ 2YDK 2YER 2YEX 2YM3 2YM4 2YM5 2YM6 2YM7 2YM8 2YWP 3F9N 3JVR 3JVS 3NLB 3OT3 3OT8 3PA3 3PA4 3PA5 3TKH 3TKI 3U9N 4FSM 4FSN 4FSQ 4FSR 4FST 4FSU 4FSW 4FSY 4FSZ 4FT0 4FT3 4FT5 4FT7 4FT9 4FTA 4FTC 4FTI 4FTJ 4FTK 4FTL 4FTM 4FTN 4FTO 4FTQ 4FTR 4FTT 4FTU 4GH2 4HYH 4HYI 4JIK 4QYE 4QYF 4QYG 4QYH 4RVK 4RVL 4RVM 5DLS 5F4N 5OOP 5OOR 5OOT 5OP2 5OP4 5OP5 5OP7 5OPB 5OPR 5OPS 5OPU 5OPV 5OQ5 5OQ6 5OQ7 5OQ8 5WI2 6FC8 6FCF 6FCK
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?